Epidemiological evolution of COVID-19 in Brazil and worldwide
DOI:
https://doi.org/10.33448/rsd-v9i7.4653Keywords:
Coronavirus; Pandemic; Epidemiology; Mortality.Abstract
Objective: to analyze the epidemiological evolution of COVID-19 in Brazil correlating to the current world scenario. Methodology: this is an analytical and documentary epidemiological study with a quantitative and descriptive approach of secondary data from COVID-19 of the Special Epidemiological Bulletin number 15 of the Ministry of Health of Brazil on the epidemiological situation until May 8, 2020. Results: the United States leads in number of confirmed cases 1,318,787 (33%) and deaths 78,503 (28%) in the world. Brazil, occupies the 8th place with 145,328 (4%) of the confirmed cases of COVID-19, its lethality is 6.8% and mortality is 46.6 per 1,000,000 inhabitants. In 2020, 107,895 hospitalizations for Severe Acute Respiratory Syndrome were registered in Brazil, of which 27,086 (25%) were confirmed cases of COVID-19 and 7,514 (28%) died, with people aged 60 or over 5,697 (69%) of the cases and heart diseases and diabetes were the risk groups that stood out considerably in the deaths of the elderly. Conclusion: the disease is not yet under control, social distance and the use of masks are the best way to prevent the progression of cases and deaths by COVID-19.
References
Brasil (2020a). Ministério da Saúde. Coronavírus (COVID-19-). MS, Recuperado em 12 de maio, 2020, https://coronavirus.saude.gov.br/.
Brasil (2020b). Ministério da Saúde. Secretaria de Vigilância em Saúde. Boletim Epidemiológico Especial COVID-19 - N15. MS, Recuperado em 12 de maio, 2020, https://portalarquivos.saude.gov.br/images/pdf/2020/May/09/2020-05-06-BEE15-Boletim-do-COE.pdf.
Cheng, P., Zhu, H., Witteles, R. M., Wu, J. C., Quertermous, T., Wu, S. M., & Rhee, J. W. (2020). Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty. Current Cardiology Reports, 22(5). doi: 10.1007/s11886-020-01293-2.
El-Aziz, T. M. A., & Stockand, J. D. (2020). Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status. Infection, Genetics and Evolution, 83(1): 104327. doi: 10.1016/j.meegid.2020.104327.
Guan, W. J., Ni, Z. Y., Hu, Y., Liang, W. H., Ou, C. Q., He, J. X., ... & Du, B. (2020a). Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine, 382(18), 1708-1720. doi: 10.1056 / NEJMoa2002032.
Guan, W. J., Liang, W. H., Zhao, Y., Liang, H. R., Chen, Z. S., Li, Y. M., ... & Ou, C. Q. (2020b). Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. European Respiratory Journal. doi: 10.1183 / 13993003.00547-2020.
Liu, Y., Gayle, A. A., Wilder-Smith, A., & Rocklöv, J. (2020). The reproductive number of COVID19 is higher compared to SARS coronavirus. Journal of Travel Medicine. doi: 10.1093/jtm/taaa021
Organização Pan-Americana da Saúde [OPAS] (2020). Folha informativa - COVID-19 (doença causada pelo novo coronavírus). Recuperado em 10 de maio, 2020, https://www.paho.org/bra/index.php?option=com_content&view=article&id=6101:covid19&Itemid=875.
Santiago, E. J. P., Freire, A. K. S., Cunha Filho, M., Moreira, G. R. Ferreira, D. S. A., & Cunha, A. L. X. (2020). Non-linear models applicable to mortality and cases of COVID-19 in Brazil, Italy and the world. Research, Society and Development, 9(6): 1-16, e117963561. doi: 10.33448/rsd-v9i6.3561.
Siordia Jr, J. A. (2020). Epidemiology and clinical features of COVID-19: A review of current literature. Journal of Clinical Virology, 104357.doi: 10.1016/j.jcv.2020.104357.
Sousa, M., Barros, S., Silva, M., Oliveira, A., Rocha, G., & Oliveira, G. (2020). Patogênese e perspectivas de tratamento da Covid-19: uma revisão. Research, Society and Development, 9(7), e05973730. doi: http://dx.doi.org/10.33448/rsd-v9i7.3730.
World Health Organization (2020). Coronavirus disease 2019 (COVID-19). WHO, Recuperado em 10 de maio, 2020, https://www.who.int/teams/blueprint/covid-19.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.